Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MONICA EUIJIN LEE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215129309
CMS profile
145487
Location
FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,691.40

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,194.30 169
Honoraria $2,100.00 1
Travel and Lodging $364.38 3
Education $32.72 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MONICA EUIJIN LEE

NPI 1215129309 · CMS profile ID 145487

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215129309?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MONICA EUIJIN LEE, NPI 1215129309, CMS profile ID 145487. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215129309?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MONICA EUIJIN LEE, NPI 1215129309, CMS profile ID 145487. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215129309?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MONICA EUIJIN LEE, NPI 1215129309, CMS profile ID 145487, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1215129309?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $6,691.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $26.5808/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197014159 CMS
Celgene Corporation $3.3108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803487 CMS
Celgene Corporation $10.3908/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803499 CMS
Celgene Corporation $9.5108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803503 CMS
Celgene Corporation $1.5108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803505 CMS
Genentech USA, Inc. $32.2908/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211555420 CMS
Ipsen Biopharmaceuticals, Inc $22.2008/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208838719 CMS
Janssen Biotech, Inc. $34.5408/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174620175 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.7508/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223936700 CMS
ABBVIE INC. $24.1708/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202283091 CMS
ABBVIE INC. $0.7008/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202283089 CMS
AstraZeneca Pharmaceuticals LP $23.4008/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206590452 CMS
Daiichi Sankyo Inc. $24.9708/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197017235 CMS
Gilead Sciences, Inc. $30.8408/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234433474 CMS
Celgene Corporation $15.5108/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803489 CMS
Celgene Corporation $1.2008/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803491 CMS
Celgene Corporation $16.4708/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803493 CMS
Celgene Corporation $2.4708/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803501 CMS
Astellas Pharma US Inc $27.9808/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238653184 CMS
E.R. Squibb & Sons, L.L.C. $23.6508/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803485 CMS
AstraZeneca Pharmaceuticals LP $19.0908/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206760277 CMS
Janssen Biotech, Inc. $37.5108/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174620640 CMS
Amgen Inc. $32.7208/01/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1226918698 CMS
GlaxoSmithKline, LLC. $33.4008/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190685433 CMS
Aveo Pharmaceuticals, Inc. $26.8407/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199900284 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.3007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223860005 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.3707/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225622438 CMS
Eisai Inc. $23.1207/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500934 CMS
AstraZeneca Pharmaceuticals LP $31.1607/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206334350 CMS
AstraZeneca Pharmaceuticals LP $22.2707/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207295744 CMS
Novartis Pharmaceuticals Corporation $30.3807/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200766812 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.5907/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223033578 CMS
ARRAY BIOPHARMA INC $21.3607/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229069458 CMS
Novartis Pharmaceuticals Corporation $17.5207/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200766810 CMS
Coherus Oncology, Inc. $21.9007/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235237955 CMS
E.R. Squibb & Sons, L.L.C. $23.2307/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803477 CMS
E.R. Squibb & Sons, L.L.C. $18.5906/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803467 CMS
PharmaEssentia USA Corporation $23.8506/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246836094 CMS
Gilead Sciences, Inc. $22.2506/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234502327 CMS
E.R. Squibb & Sons, L.L.C. $18.5206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184803463 CMS
Lilly USA, LLC $21.5006/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186844241 CMS
Gilead Sciences, Inc. $32.5306/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234426068 CMS
ABBVIE INC. $23.6006/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202283087 CMS
AstraZeneca Pharmaceuticals LP $19.3306/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206498220 CMS
Merck Sharp & Dohme LLC $26.7106/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238196264 CMS
Exelixis Inc. $32.4806/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218799771 CMS
Merck Sharp & Dohme LLC $20.5006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238386716 CMS
GlaxoSmithKline, LLC. $10.2506/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190394732 CMS
Medexus Pharma, Inc. $63.3406/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223514239 CMS
Daiichi Sankyo Inc. $26.0105/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197080919 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,399.26 82
PY2020 $396.28 21
PY2021 $723.43 18
PY2022 $2,229.98 94
PY2023 $5,329.14 108
PY2024 $7,770.33 136
PY2025 $6,691.40 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $459,327.15 15
PY2024 Principal investigator $54,115.37 3
PY2023 Principal investigator $38,301.10 5
PY2022 Principal investigator $152,079.97 4
PY2021 Recipient $480.95 1
PY2021 Principal investigator $71,661.30 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $304,880.54 12/31/2025 Non-covered Recipient Entity
Providence Medical Foundation-Oncology
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer No dispute reported 06/30/2026 1232923070
Principal investigator 1 Merck Sharp & Dohme LLC $61,401.96 12/31/2025 Non-covered Recipient Entity
Providence Medical Foundation
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl No dispute reported 06/30/2026 1232924962
Principal investigator 1 ABBVIE INC. $490.00 09/16/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202511090
Principal investigator 1 ABBVIE INC. $400.00 09/04/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202510054
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,863.30 08/29/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185552993
Principal investigator 1 ABBVIE INC. $455.00 06/18/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202492357
Principal investigator 1 ABBVIE INC. $16,727.90 06/04/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202490141
Principal investigator 1 ABBVIE INC. $652.04 05/27/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202486303
Principal investigator 1 ABBVIE INC. $9,523.08 05/21/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202485697
Principal investigator 1 ABBVIE INC. $9,668.99 05/21/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202485699
Principal investigator 1 ABBVIE INC. $455.00 05/15/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202485239
Principal investigator 1 ABBVIE INC. $6,870.00 04/30/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202480647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,896.00 02/12/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185552991
Principal investigator 1 ABBVIE INC. $10,158.68 01/29/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202442995
Principal investigator 1 ABBVIE INC. $18,884.66 01/14/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202438561